Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: A randomized, double-blind, placebo-controlled study

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 289-296

  Lohr, James B ^a,b,c   Liu, Lianqi ^a,b,c   Caligiuri, Michael P ^a   Kash, Taylor P ^b   May, Todd A ^a,b   Murphy, Jody DelaPena ^a,b,c   Ancoli Israel, Sonia ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VA CENTER OF EXCELLENCE FOR STRESS AND MENTAL HEALTH   (United States)

Author keywords

Cognition; Excessive daytime sleepiness; Modafinil; Negative symptoms; Parkinsonism; Schizophrenia

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BENZATROPINE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DIPHENHYDRAMINE; FLUOXETINE; GABAPENTIN; HALOPERIDOL; IPRATROPIUM BROMIDE; LORAZEPAM; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; TEMAZEPAM; TRAZODONE; TRIHEXYPHENIDYL; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; BACKACHE; BODY TEMPERATURE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DELUSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; HEART RATE; HEARTBURN; HIP PAIN; HUMAN; HYPOTENSION; IRRITABILITY; MALE; MOTOR DYSFUNCTION; NECK PAIN; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; PARANOIA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

COGNITION; EXCESSIVE DAYTIME SLEEPINESS; MODAFINIL; NEGATIVE SYMPTOMS; PARKINSONISM; SCHIZOPHRENIA;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZHYDRYL COMPOUNDS; COGNITION DISORDERS; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WAKEFULNESS-PROMOTING AGENTS; YOUNG ADULT;

EID: 84884159055     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.039     Document Type: Article

References (54)

1. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67:255-262.
2. Arbabi M., Bagheri M., Rezaei F., Ahmadi-Abhari S.A., Tabrizi M., Khalighi-Sigaroudi F., Akhondzadeh S. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology (Berl). 2012, 220:591-598.
3. Ballon J.S., Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatry 2006, 67:554-566.
4. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Bobo W.V., Woodward N.D., Sim M.Y., Jayathilake K., Meltzer H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr. Res. 2011, 130:106-113.
6. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin. Neuropsychol. 1991, 5:125-142.
7. Caligiuri M.P., Lohr J.B. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients. J. Neuropsychiatry. Clin. Neurosci. 1997, 9:562-567.
8. Caligiuri M.P., Lohr J.B., Jeste D.V. Parkinsonism in neuroleptic-naive schizophrenic patients. Am. J. Psychiatry 1993, 150:1343-1348.
9. Correll C.U. What are we looking for in new antipsychotics?. J. Clin. Psychiatry 2011, 72(Suppl. 1):9-13.
10. Darwish M., Kirby M., Robertson P., Hellriegel E.T. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin. Pharmacokinet. 2008, 47:61-74.
11. Desmarais J.E., Beauclair L., Margolese H.C. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?. J. Psychopharmacol. 2012, 26:1167-1174.
12. Ferraro L., Fuxe K., Tanganelli S., Tomasini M.C., Rambert F.A., Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J. Neurosci. Res. 2002, 68:107-112.
13. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
14. Freudenreich O., Henderson D.C., Macklin E.A., Evins A.E., Fan X., Cather C., Walsh J.P., Goff D.C. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 2009, 70:1674-1680.
15. Gerrard P., Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr. Dis. Treat. 2007, 3:349-364.
16. Golden C.J. Stroop Color and Word Test: A Manual For Clinical and Experimental Uses Stoelting Co 1978, Wood Dale, IL.
17. Golicki D., Bala M.M., Niewada M., Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Med. Sci. Monit. 2010, 16:RA177-RA186.
18. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, revised 1976, 534-537. National Institute of Mental Health, Rockville. N. Psychopharmacology Research Branch (Ed.).
19. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338) 1976, 218-222. U.S.Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
20. Heaton R.K. The Wisconsin Card Sorting Test: 64 card research edition Psychological Assessment Resources, Inc. 1998, (Odessa, Fl).
21. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry 2006, 163:2184-2186.
22. Jaffe F., Markov D., Doghramji K. Sleep-disordered breathing: in depression and schizophrenia. Psychiatry (Edgmont) 2006, 3:62-68.
23. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
24. Kane J.M., D'Souza D.C., Patkar A.A., Youakim J.M., Tiller J.M., Yang R., Keefe R.S. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry 2010, 71:1475-1481.
25. Kane J.M., Yang R., Youakim J.M. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr. Res. 2012, 135:116-122.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
27. Keating G.M., Raffin M.J. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. Cns Drugs 2005, 19:785-803.
28. Meltzer H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64:393-406.
29. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
30. Mitchell H.A., Bogenpohl J.W., Liles L.C., Epstein M.P., Bozyczko-Coyne D., Williams M., Weinshenker D. Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action. Pharmacol. Biochem. Behav. 2008, 91:217-222.
31. Morrens M., Hulstijn W., Sabbe B. Psychomotor slowing in schizophrenia. Schizophr. Bull. 2007, 33:1038-1053.
32. Narendran R., Young C.M., Valenti A.M., Nickolova M.K., Pristach C.A. Is psychosis exacerbated by modafinil?. Arch. Gen. Psychiatry 2002, 59:292-293.
33. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 2007, 68:705-710.
34. Plante D.T. Treatment-emergent hypomania or mania with modafinil. Am. J. Psychiatry 2008, 165:134-135.
35. Reitan R.M., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation 1998, Neuropsychology Press, Tucson, Az. 2nd Edition.
36. Rosenthal M.H., Bryant S.L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin. Neuropharmacol. 2004, 27:38-43.
37. Rosenthal L.D., Dolan D.C. The Epworth sleepiness scale in the identification of obstructive sleep apnea. J. Nerv. Ment. Dis. 2008, 196:429-431.
38. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., Davis J.M., Leucht S. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 2012, 38:167-177.
39. Saavedra-Velez C., Yusim A., Anbarasan D., Lindenmayer J.P. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J. Clin. Psychiatry 2009, 70:104-112.
40. Scoriels L., Barnett J.H., Soma P.K., Sahakian B.J., Jones P.B. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology (Berl) 2012, 220:249-258.
41. Scoriels L., Jones P.B., Sahakian B.J. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 2013, 64:168-184.
42. Sevy S., Rosenthal M.H., Alvir J., Meyer S., Visweswaraiah H., Gunduz-Bruce H., Schooler N.R. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry 2005, 66:839-843.
43. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
44. Spreen O., Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms and Commentary 1998, Oxford University Press, New York. 2nd Edition.
45. Susatia F., Fernandez H.H. Drug-induced parkinsonism. Curr. Treat Options Neurol. 2009, 11:162-169.
46. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J. Clin. Psychiatry 2011, 72(Suppl. 1):4-8.
47. Urichuk L., Prior T.I., Dursun S., Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008, 9:410-418.
48. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009, 301:1148-1154.
49. Walther S., Strik W. Motor symptoms and schizophrenia. Neuropsychobiology 2012, 66:77-92.
50. Wechsler D. Wechsler Adult Intelligence Scale 1997, (WAIS-III) The Psychological Corporation, San Antonio, Tx. 3rd Edition.
51. Wolf J., Fiedler U., Anghelescu I., Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J. Clin. Psychiatry 2006, 67:1817.
52. Wu P., Jones S., Ryan C.J., Michail D., Robinson T.D. Modafinil-induced psychosis. Intern. Med. J. 2008, 38:677-678.
53. Xiao Y.L., Fu J.M., Dong Z., Yang J.Q., Zeng F.X., Zhu L.X., He B.C. Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol. Sin. 2004, 25:301-305.
54. Young J.W., Kooistra K., Geyer M.A. Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacol. 2011, 36:1385-1396.